Skip to main content

Table 1 Demographic and clinical characteristics of 32 patients infected with CRF65_cpx

From: Natural presence of the V179D and K103R/V179D mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors in HIV-1 CRF65_cpx strains

Accession numberSubtype in the databaseSexRisk factorSampling yearGeographic originARTNNRTI resistance mutations
MG706585CRF65_cpxMMSM2014HebeiTreatment naiveV179D
KP698506CRF65_cpxMNA2011NATreatment naiveV179D
KT379558CMMSM2012GuangdongTreatment naiveV179D
KR823099CMMSM2014BeijingTreatment naiveV179D
JQ898223CRF65_cpxMIDU2009YunnanTreatment experiencedV179D, Y181C, H221Y
KR822879CMMSM2010BeijingTreatment naiveV179D
MG706490CRF65_cpxMMSM2014HebeiTreatment naiveV179D
KP250691CMMSM2009BeijingTreatment naiveV179D
MG706508CRF65_cpxMMSM2014HebeiTreatment naiveV179D
KP698505CRF65_cpxMMSM2010BeijingTreatment naiveV179D
KP698503CRF65_cpxMMSM2010BeijingTreatment naiveV179D
KX198586CRF65_cpxMMSM2013HebeiTreatment naiveK103R, V179D
KF714341CFHET2009YunnanTreatment naiveV179D
KP698508CRF65_cpxMMSM2012BeijingTreatment naiveK103R, V179D
KP698504CRF65_cpxMMSM2010BeijingTreatment naiveK103R, V179D
KF714427CMHET2011YunnanTreatment naiveV179D
KR822921CMMSM2011BeijingTreatment naiveK103R, V179D
KC183778CRF65_cpxMMSM2011AnhuiTreatment naiveK103R, V179D
KF714326CMHET2009YunnanTreatment naiveV179D
KP698507CRF65_cpxMMSM2012BeijingTreatment naiveV179D
KY713419CMMSM2016BeijingTreatment naiveK103R, V179D
KF714479CFHET2012YunnanTreatment naiveV179D
MH051841CRF65_cpxMMSM2015JilinTreatment naiveK103R, V179D
KF714310CFHET2009YunnanTreatment naiveV179D
KF714461CFHET2012YunnanTreatment naiveE138A, V179D
KC870030CRF65_cpxMHET2009YunnanTreatment naiveV179D
KC870027CRF65_cpxFHET2010YunnanTreatment naiveV179D
KF714363CFHET2010YunnanTreatment naiveV179D
MF941253CNANA2014HeilongjiangTreatment naiveK103R, V179E
KT625846CRF65_cpxNANA2013YunnanTreatment naiveV179D
KC870028CRF65_cpxFHET2010YunnanTreatment naiveV179D
KF714374BCFHET2010YunnanTreatment naiveV179D
  1. ART antiretroviral therapy, M male, F female, HET heterosexual, IDU intravenous drug user, MSM men who have sex with men, NA not available